RecruitingPhase 2Drug trialMethotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSLPilot-trial of Methotrexate, Tafasitamab (Minjuvi®), Lenalidomide (Revlimid®) and Rituximab in patients ineligible for HCT-ASCT with Primary Central Nervous System Lymphoma (PCNSL)